Poseida Therapeutics Inc
General ticker "PSTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $850.5M
Poseida Therapeutics Inc follows the US Stock Market performance with the rate: 25.7%.
Estimated limits based on current volatility of 1.8%: low 9.40$, high 9.50$
Factors to consider:
- Current price 72.1% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [2.37$, 5.51$]
- 2024-12-30 to 2025-12-30 estimated range: [2.24$, 5.25$]
Financial Metrics affecting the PSTX estimates:
- Negative: Non-GAAP EPS, $ of -1.39 <= 0.10
- Negative: Operating profit margin, % of -66.68 <= 1.03
- Negative: Operating cash flow per share per price, % of -25.35 <= 2.35
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
- Negative: Industry operating profit margin (median), % of -98.30 <= 2.14
Short-term PSTX quotes
Long-term PSTX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $31.24MM | $130.49MM | $64.70MM |
| Operating Expenses | $172.65MM | $190.44MM | $194.21MM |
| Operating Income | $-141.41MM | $-59.95MM | $-129.50MM |
| Non-Operating Income | $16.44MM | $-3.51MM | $6.18MM |
| Interest Expense | $0.00MM | $6.37MM | $8.67MM |
| R&D Expense | $0.14MM | $152.90MM | $156.77MM |
| Income(Loss) | $-124.97MM | $-63.46MM | $-123.32MM |
| Taxes | $0.00MM | $0.54MM | $0.11MM |
| Profit(Loss) | $-124.97MM | $-64.00MM | $-123.43MM |
| Stockholders Equity | $156.21MM | $187.59MM | $103.70MM |
| Inventory | $0.00MM | $4.46MM | $0.00MM |
| Assets | $269.31MM | $351.84MM | $273.88MM |
| Operating Cash Flow | $-102.54MM | $-26.77MM | $-92.17MM |
| Capital expenditure | $2.63MM | $3.92MM | $3.07MM |
| Investing Cash Flow | $222.38MM | $-203.33MM | $39.13MM |
| Financing Cash Flow | $2.52MM | $105.16MM | $16.13MM |
| Earnings Per Share* | $-0.07 | $-0.89 | $-1.37 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.